KBL Merger Corp. IV KBLM on Friday announced its acquisition of a new cannabis biotech company CannBioRx Life Sciences Corp.
CannBioRx Life Sciences Corp. has three synergistic programs that operate at the intersection of biotech and cannabis, and focuses on developing novel anti-inflammatory drugs for diseases like Crohn's and multiple sclerosis.
Latest Startup Investment Opportunities:
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!
The company was founded by Sir Marc Feldmann of Oxford and Lawrence Steinman of Stanford, who have significant expertise in developing successful therapeutics that resulted in billion-dollar markets, including blockbusters like Johnson & Johnson JNJ’s Remicade.
"We expect to be one of a limited number of NASDAQ-listed companies developing non-plant-touching, pharmaceutical-grade, non-psychoactive cannabinoids. These drugs are intended to provide safer, uniform dosing, according to regulatory agency standards," said Dr. Marlene Krauss, CEO of KBLM, who will also assume the role of CEO of CannBioRx Life Sciences Corp.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
